ArticleCell death & disease2026
FERPIR promotes cardiomyocyte survival and attenuates cardiac remodeling after myocardial infarction.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PIWI-interacting RNAs (piRNAs) are widely expressed in cardiac tissues and play important roles in cardiac pathophysiology. However, their functions and molecular mechanisms in cardiac remodeling following myocardial infarction (MI) and cardiomyocyte ferroptosis remain largely unknown. Here, we identified a ferroptosis-related piRNA (FERPIR), which inhibits ischemia/reperfusion (I/R) induced myocardial injury, cardiac remodeling and ferroptosis by targeting HNRNPA2B1-dependent regulation of Fis1. FERPIR levels were decreased in hypoxia/reoxygenation (H/R)-exposed cardiomyocytes and I/R-injured mouse hearts. FERPIR prevented I/R-induced acute injury and pathological cardiac remodeling. In vitro, overexpression of FERPIR inhibits H/R-induced ferroptosis. Mechanistically, FERPIR directly bound to HNRNPA2B1 and promoted its stability, which exhibited decreased ferroptosis and improved cardiac function upon I/R injury. Fis1 acted as a downstream regulator of HNRNPA2B1, and FERPIR recruited HNRNPA2B1 to bind to Fis1 mRNA and decreased its stability, thereby inhibiting mitochondrial fission and ferroptosis, which improves cardiac remodeling after myocardial infarction. Our findings reveal that FERPIR prevents myocardial I/R induced injury and pathological cardiac remodeling through the HNPA2B1/Fis1 axis, which provides potential therapeutic targets against cardiac injury caused by cardiomyocyte ferroptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.